思连康治疗肝硬化腹泻的疗效观察  

Observation of curative effect of silico on liver cirrhosis-related diarrhea

作　　者：薛鸿鹏[1] 祝喜萍[1] 陆以霞[1] 孙媛媛[1] 郭文敏[1] 

机构地区：[1]黑龙江省医院附属消化病医院,黑龙江哈尔滨150001

出　　处：《中国医学装备》2009年第6期39-40,共2页China Medical Equipment

摘　　要：目的:观察思连康治疗肝硬化腹泻的疗效。方法:83例病人随机分成两组,治疗组41例,口服思连康(每次两粒,每日三次)2周;对照组42例,口服思密达(每次一袋,每日三次)2周。结果:治疗组有效率为87.80%,对照组有效率为64.28%,两组间比较有显著性差异(P<0.01)。结论:思连康是治疗肝硬化腹泻的有效药物。Objective： To observe the curative effect of silico on liver cirrhosis - related diarrhea. Methods： A total of 85 patients were divided into two groups randomly. Forty-one 41 cases in the experimental group took silico orally （two pills toties quoties, tid） for two weeks and 42 in the control group took Smecta （dioctahedral smectite） orally （one pouch toties quoties, tid） for two weeks. Results： The effective rates were 87.80% and 64.28% in the experimental group and the control group, respectively. There was significant difference between the 2 groups （p〈0.01）. Conclusion： Silico is effective for treatment of liver cirrhosis- related diarrhea.

关 键 词：思连康 肝硬化 腹泻 

分 类 号：R562[医药卫生—呼吸系统]